The TRIUMPH-3 clinical trial for retatrutide began in April 2022 and enrolled adults with obesity who are at high risk for cardiovascular disease or heart disease
Currently available GLP-1 receptor agonists include: Exenatide (Byetta, Bydureon BCise) : Available as twice-daily or once-weekly formulations
Clinical trial data on Retatrutides benefits is striking: Weight loss up to 24% of total body weight within 48 weeks outpacing both semaglutide and tirzepatide in head-to-head comparisons 3050% reduction in appetite , making dietary adherence significantly easier Visceral fat reduction of up to 40%, targeting the most metabolically harmful fat stored around organs Improved glycemic control and reduced insulin resistance, with benefits for those at risk of or managing type 2 diabetes Liver health improvement emerging data suggests positive effects on non-alcoholic fatty liver disease (NAFLD) Elevated resting energy expenditure , meaning your body burns more calories at rest For residents of Dubai pursuing sustainable, medically supervised weight management, these outcomes represent a meaningful leap forward
Minimised Facial Volume Loss: Slower weight loss helps maintain a natural, balanced appearance
Avoid cooking strong-smelling foods when nausea is at its peak
Because tirzepatide can amplify the blood pressure-lowering effects of these drugs, healthcare providers may need to adjust doses
